Agency / Source: Greystone Associates

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Greystone Associates Analyzes the Impact of Proprietary Formulation Technologies on Key Therapeutic Markets - As the pharmaceutical industry attempts to improve productivity and lower the business risks associated with new drug candidates, drug developers are increasingly turning to a generation of new, often proprietary, formulation and delivery technologies
Greystone Associates Analyzes the Impact of Proprietary Formulation Technologies on Key Therapeutic Markets

 

PRZOOM - /newswire/ - Amherst, NH, United States, 2010/01/11 - As the pharmaceutical industry attempts to improve productivity and lower the business risks associated with new drug candidates, drug developers are increasingly turning to a generation of new, often proprietary, formulation and delivery technologies.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

These technologies can modulate release profiles to achieve dosage forms that enhance patient outcomes, compliance and safety. Controlled-release oral dosage forms can often yield a decrease in the dosing frequency and a reduction in peak plasma concentrations.

Drug formulation technology companies are working with drug developers to help define the prescription formulations that will enter preclinical development and the clinical trial pipeline in the coming months and years. The formulation capabilities will expand the number of new NCEs that can be formulated to meet pharmacochemical thresholds.

Growth in controlled release formulations is driven in part by the dramatic increase in generic drugs and generic drug companies. These off-patent APIs often suffer from sub-optimal pharmacokinetics and unpleasant side effects, issues which can often be addressed by proprietary formulation platforms. As generic drug suppliers search for ways to increase the marketability and positioning of their products, the number of controlled release technology formulations entering the marketplace will accelerate.

A new report examines the implications of these trends on pharmaceutical drug discovery and development. Controlled Release Drug Delivery Systems: Technology, Therapeutics Demand Factors and Prospects contains analysis of commercial modified release drug technologies, assessments of market, technology and demand factors, and profiles of drug formulation technology companies.

More information is available at Greystone Associates on the web.

About Greystone

Greystone Associates (greystoneassociates.org) is a medical technology consulting firm focused on the areas of medical market strategy, product commercialization, venture development, and market research. We assist medical and healthcare market participants in achieving their business objectives through the creation of detailed development strategies, product commercialization programs, and comprehensive market and technology research and analysis. Our market research publications are designed, researched and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge to refine and execute their marketing plans and financial targets.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Greystone Associates

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Greystone Associates Analyzes the Impact of Proprietary Formulation Technologies on Key Therapeutic Markets

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Mark Smith - GreystoneAssociates.org 
603-595-4340 mksmith[.]greystoneassociates.org
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Greystone Associates securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Press Releases From Greystone Associates / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Press Releases:

DSM and the World Food Programme Partner to Improve Nutrition Around the World
European Commission Approves Cabometyx® as A Second-line Treatment for People Living with Radioactive Iodine-refractory Differentiated Thyroid Cancer
Shionogi and NEC Enter into Strategic Research Collaboration for Novel Hepatitis B Therapeutic Vaccine
Boehringer Ingelheim Selects Veeva Development Cloud Worldwide to Bring Innovative Therapies to Patients Faster
Ipsen Announces Investment in New State-of-the-art Electronic Autoinjector for Somatuline® Autogel® / Somatuline® Depot (lanreotide)
NEC OncoImmunity Acquires VAXIMM’s Neoantigen Vaccine Development Assets
Veeva Widely Recognized for Leadership and Innovation in Support of Customers and Employees
Veeva Vault CDMS Selected by Idorsia to Modernize Clinical Data Management
Bruker BioSpin Group Introduces New Online Platform to Connect NMR Scientists and Advance NMR Research in Europe
LYSARC Partners with Veeva to Accelerate Innovation for Lymphoma Treatments

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
.



PREMIUM Members


Visit  RightITnow, Inc.

Visit  BizJobs.com

Visit  Limelon Advertising, Co.







 
  ©2022 PRZOOM - Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today